The mice drank water that was 6% arginine, starting at five weeks of age. By the time they were six months old, the brains of these animals, bred to grow Alzheimer’s-style plaques, held clearly less of the sticky protein than their untreated littermates.
The work comes from a team at Kindai University in Osaka, and it appeared in Neurochemistry International. Their subject, arginine, is an amino acid found in foods such as pumpkin and meat, and it already has a place in treating several diseases. It also works as a chaperone, a helper that guides other proteins into the right shape. Misfolded amyloid beta clumps into fibrils and then plaques, the best-known sign of Alzheimer’s, so the question was simple: could a folding helper keep the clumps from forming?
Dish, flies, mice
In the dish, arginine cut fibril formation in a dose-dependent way, by up to roughly 80% at 1 mM. A green tea compound, EGCG, did better in that test. The team left it out of the animal work, and Lifespan.io points to its poor oral bioavailability and signs of liver toxicity at therapeutic doses.
Next came fruit flies engineered to make human amyloid beta in the eye. Arginine lowered the fraction of cells carrying aggregates, and the shrinking of the eye, a sign of toxicity in this model, eased too. Protein production itself did not change, which suggests the amino acid affected clumping or clearance.
The mouse results were more mixed. At 6 months, plaque area and number fell in the cortex and the hippocampus, and insoluble amyloid beta 42 dropped significantly. At 9 months the effect faded to a nonsignificant trend in the hippocampus, probably because plaques had nearly reached their ceiling by then. Fewer dense-core plaques showed up at both ages. In a Y-maze test of memory and anxiety, treated mice did significantly better at 9 months but showed only a weak trend at 6, which the report notes sits oddly with the plaque data. Inflammatory markers IL-1β, IL-6 and TNF-α were all significantly lower in the cortex.
A cheap candidate, with limits
“What makes this finding exciting is that arginine is already known to be clinically safe and inexpensive,” said Professor Yoshitaka Nagai, who leads the work, calling it a promising candidate for repositioning as an Alzheimer’s therapy. Arginine has clinical approval in Japan for other uses and crosses into the brain, so he argues it could be “rapidly translated to clinical trials.”
The researchers are careful not to sell this as a shop-shelf fix. Converted to human terms, the mouse dose equals 940 mg/kg/day, roughly double the highest oral dose Japan has approved for urea cycle disorders. They stress that the regimen was designed for research and does not match commercial supplements, and that further lab work and human trials must show whether any of it holds in people.
For now the evidence stops at flies and mice. Antibody drugs aimed at amyloid beta have delivered modest gains, cost a lot and can trigger immune reactions, and that is the gap the team hopes a cheap oral compound could fill.
Sources
- Arginine Reduces Signs of Alzheimer's in Mice (Lifespan.io)
- This simple amino acid supplement greatly reduces Alzheimer's damage (ScienceDaily, Kindai University)
- Japanese study reveals arginine can reduce Alzheimer's disease markers (Nutrition Insight)
